GSK offloads gene therapy portfolio and takes stake in Orchard
GlaxoSmithKline has sold a number of gene therapy products – including its approved autologous ex vivo product Strimvelis – to Orchard Therapeutics.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs